Radioactivity Concentration in the Air during Peptide Receptor Radionuclide Therapy with [<sup>177</sup>Lu]Lu-oxodotreotide

DOI Web Site
  • Takano Shoko
    Department of Radiation Oncology, Yokohama City University Graduate School of Medicine
  • Ogawa Matsuyoshi
    Radiation department, Yokohama City University Hospital
  • Kobayashi Noritoshi
    Department of Oncology, Yokohama City University Graduate School of Medicine
  • Ichikawa Yasushi
    Department of Oncology, Yokohama City University Graduate School of Medicine
  • Hosono Makoto
    Department of Radiation Oncology, Faculty of Medicine, Kindai University
  • Hata Masaharu
    Department of Radiation Oncology, Yokohama City University Graduate School of Medicine

Bibliographic Information

Other Title
  • <sup>177</sup>Lu標識ルテチウムオキソドトレオチドを用いたペプチド受容体核医学治療の空気中の放射能濃度

Search this article

Abstract

<p>[177Lu]Lu-oxodotreotide is a peptide receptor radionuclide therapy (PRRT) agent. The concentration of radioactive materials in the air was measured on patients during treatment with this drug. The concentration of lutetium (177Lu) in the air was below the detection limit in the administration room and the waiting room, while it was detected in some cases in the special measures patient room. However, the detected levels were well below the concentration limits on radioisotopes specified in the second column of Appendix 3 of the Ordinance for Enforcement of the Medical Service Act.</p>

Journal

  • RADIOISOTOPES

    RADIOISOTOPES 71 (2), 135-140, 2022-07-15

    Japan Radioisotope Association

Keywords

Details 詳細情報について

Report a problem

Back to top